Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1328-1338

  Wolanin, Kamila ^a   Magalska, Adriana ^a   Kusio Kobialka, Monika ^a   Podszywalow Bartnicka, Paulina ^a   Vejda, Susanne ^b   McKenna, Sharon L ^b   Mosieniak, Grazyna ^a   Sikora, Ewa ^a   Piwocka, Katarzyna ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BCR ABL PROTEIN; BETA ACTIN; BRCA1 PROTEIN; BUB1 RELATED PROTEIN; BUB3 PROTEIN; CYCLIN B1; IMATINIB; NOCODAZOLE; PROTEIN BUB1; PROTEIN MAD2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANIMAL CELL; ARTICLE; CANCER PATIENT; CELL CYCLE PHASE; CELL DIVISION; CHROMOSOME SEGREGATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE EXPRESSION; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; ONCOGENE; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANEUPLOIDY; ANIMALS; CELL DIVISION; CELLS, CULTURED; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, CDC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICROTUBULES; MITOSIS; PROTEIN-TYROSINE KINASES; TUBULIN MODULATORS;

EID: 77952171995     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0936     Document Type: Article

References (36)

1. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103:4010-4022
2. Amiel A, Yukla M, Gaber E, et al. Random aneuploidy in CML patients at diagnosis and under imatinib treatment. Cancer Genet Cytogenet 2006;168:120-123
3. Babicka L, Zemanova Z, Pavlistova L, et al. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2006;168:22-29 (Pubitemid 43870196)
4. Giehl M, Fabarius A, Frank O, et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005;19:1192-1197 (Pubitemid 40946003)
5. Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007;26:11-20. (Pubitemid 46067327)
6. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-453 (Pubitemid 46823444)
7. Deutsch E, Jarrousse S, Buet D, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003;101:4583-4588
8. Bae I, Rih JK, Kim HJ, et al. BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle 2005;4:1641-1666
9. Wang RH, Yu H, Deng CX. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci U S A 2004;101:17108-17113
10. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007;8:379-393
11. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-2027
12. Taylor SS, Scott MI, Holland AJ. The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation. Chromosome Res 2004;12:599-616.
13. Wolanin K, Magalska A, Mosieniak G, et al. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol Cancer Res 2006;4:457-469
14. Keeshan K, Cotter TG, McKenna SL. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 2002;16:1725-1734
15. Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001;15:1823-1833
16. Mantel C, Guo Y, Lee MR, et al. Cells enter a unique intermediate 4N stage, not 4N-G1, after aborted mitosis. Cell Cycle 2008;7: 484-492
17. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004;23:6845-6853
18. Brusa G, Benvenuti M, Mazzacurati L, et al. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. Haematologica 2003;88:622-30.
19. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004;18:545-568, vii-viii.
20. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of disease initiation and progression. Leuk Lymphoma 1993;11 Suppl 1:47-50.
21. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006;5: 1001-1007
22. Mullan P, Quinn J, Harkin D. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-5863
23. Wang X, Cheung HW, Chun AC, Jin DY, Wong YC. Mitotic checkpoint defects in human cancers and their implications to chemotherapy. Front Biosci 2008;13:2103-2114
24. Dai W, Wang Q, Liu T, et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 2004;64:440-445
25. Kienitz A, Vogel C, Morales I, Muller R, Bastians H. Partial down-regulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005;24:4301-4310
26. Babu JR, Jeganathan KB, Baker DJ, Wu X, Kang-Decker N, van Deursen JM. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol 2003;160:341-353
27. Baker DJ, Jeganathan KB, Cameron JD, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet 2004;36:744-749
28. Michel LS, Liberal V, Chatterjee A, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001;409:355-359
29. Jeong SJ, Shin HJ, Kim SJ, et al. Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Res 2004;64:8666-8673
30. Wang X, Jin DY, Ng RW, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002; 62:1662-1668 (Pubitemid 34408486)
31. Sotillo R, Hernando E, Diaz-Rodriguez E, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.CancerCell 2007;11:9-23.
32. Yamamoto Y, Matsuyama H, Chochi Y, et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 2007;174:42-47 (Pubitemid 46365984)
33. Duensing A, Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 2005; 331:694-700. (Pubitemid 40615499)
34. Blagosklonny MV. Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. Cell Cycle 2006;5:971-975
35. Yamada H, Gorbsky G. Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol Cancer Ther 2006;5:2963-2969 (Pubitemid 46092037)
36. Ilaria RL, Jr. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology (Am Soc Hematol Educ Program) 2005:188-194